Know Cancer

or
forgot password

Bioavailability and Effectiveness of Transdermally Administered Morphine


Phase 1
18 Years
65 Years
Not Enrolling
Both
Cancer, Pain

Thank you

Trial Information

Bioavailability and Effectiveness of Transdermally Administered Morphine


Patients will participate in two arms of the trial, one in which morphine will be
administered transdermally, and, after a 3 day wash out period, one in which morphine will
be administered subcutaneously. Blood draws will be done after both dosing methods in order
to compare blood levels of morphine by the different routes.


Inclusion Criteria:



- Chronic cancer pain

- Minimum baseline pain of 3/10

- No change in medications over 3 days prior to study period

- Ability to give informed consent

- Willingness to undergo repeated blood sampling

Exclusion Criteria:

- Use of morphine or codeine in 3 days prior to study

- Known sensitivity to morphine

- Prior anaphylactic reaction to any opioid

- Clinically significant anemia

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

detectable morphine levels in serum

Principal Investigator

Neil Hagen

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Cancerboard

Authority:

Canada: Health Canada

Study ID:

10181

NCT ID:

NCT00125684

Start Date:

July 2003

Completion Date:

July 2008

Related Keywords:

  • Cancer
  • Pain
  • transdermal morphine
  • cancer
  • pain
  • bioavailability
  • pharmacokinetics
  • cancer related pain
  • stable baseline pain
  • currently taking opioids

Name

Location